Treatment for mild cognitive impairment: systematic review.
Level 1 - systematic review of randomized trials
Systematic review of randomized controlled trials
PubMed 24085737 · doi:10.1192/bjp.bp.113.127811
What was done
Authors systematically reviewed 41 randomized controlled trials evaluating any pharmacological or non-pharmacological intervention for mild cognitive impairment (MCI). Evaluated outcomes included cognitive, neuropsychiatric, functional, global, quality of life, or incident dementia. Validity was appraised with a checklist, standardized outcomes were calculated, and primary outcome findings in placebo-controlled studies were prioritized.
What was found
The abstract provides no numerical data, effect sizes, or confidence intervals. Cholinesterase inhibitors and rofecoxib did not reduce incident dementia. Single trials reported cognitive improvements for a psychological group intervention (6 months), piribedil (3 months), and donepezil (48 weeks), and attention improvements for nicotine (6 months). Evidence for Huannao Yicong was equivocal. Overall, there was no replicated evidence that any intervention was effective.
Why it matters
This review establishes that standard Alzheimer's medications like cholinesterase inhibitors do not prevent progression from MCI to dementia, underscoring the lack of proven disease-modifying treatments.
Limits
The abstract does not report the total participant sample size across the 41 studies. Positive findings were derived from isolated single trials with short durations (3 to 12 months) and have not been replicated.
Cited by
- supports Research shows that nicotine supplementation can improve cognitive function in individuals with mild cognitive impairment or dementia.